Laboratory of Pharmacology, Medical School, Democritus University of Thrace, Alexandroupolis, 68100, Greece.
Department of Medical Oncology, University General Hospital of Alexandroupolis, Medical School, Democritus University of Thrace, Alexandroupolis, 68100, Greece.
Pharmacogenomics. 2021 Jul;22(11):669-680. doi: 10.2217/pgs-2021-0031. Epub 2021 Jun 8.
gene encodes for TS enzyme involved in 5-fluorouracil (5-FU) and capecitabine (CAP) metabolism. This study assessed the association of -TSER and 3RG>C polymorphisms with 5-FU/CAP adverse event (AE) incidence. -TSER and 3RG>C polymorphisms were analyzed by use of PCR/PCR-RFLP in 313 5-FU/CAP-treated cancer patients. Female -TSER 2R carriers were at increased risk for 5-FU/CAP AEs (odds ratio: 2.195; p = 0.032). 2R/2R genotype was the only factor that increased risk for delayed drug administration or therapy discontinuation (odds ratio: 5.049; p = 0.016). No other associations were found. -TSER 3R/2R polymorphism was associated with incidence of AEs in female cancer patients. This gender-driven association potentially implicates the ER that, in female patients, potentially regulates TS expression.
该基因编码参与 5-氟尿嘧啶（5-FU）和卡培他滨（CAP）代谢的 TS 酶。本研究评估了-TSER 和 3RG>C 多态性与 5-FU/CAP 不良事件（AE）发生率的关系。通过 PCR/PCR-RFLP 在 313 名接受 5-FU/CAP 治疗的癌症患者中分析了-TSER 和 3RG>C 多态性。女性 -TSER 2R 携带者发生 5-FU/CAP AE 的风险增加（优势比：2.195；p=0.032）。2R/2R 基因型是唯一增加延迟药物给药或治疗中断风险的因素（优势比：5.049；p=0.016）。未发现其他相关性。-TSER 3R/2R 多态性与女性癌症患者 AE 的发生有关。这种性别驱动的相关性可能暗示了 ER，在女性患者中，ER 可能调节 TS 的表达。
